UT Health San Antonio readies for $38 million human trial to see whether three existing medicines can help people stay healthier for longer.
Longevity science has, time and time again, been rich in possibilities and poor in proof. Researchers have shown that aging can be nudged in animals. Mice live longer. Lab systems respond. Biological pathways look promising. But translating that into something that actually matters for people – more years of good health, fewer years of decline – has remained frustratingly out of reach.
Now, UT Health San Antonio is preparing to test one of the field’s most important questions in a way that feels unusually grounded: can three drugs that already exist help slow some of the biological processes behind aging in humans?
The study, called VITAL-H, will examine rapamycin, semaglutide and dapagliflozin in a large human clinical trial backed by $38 million in federal contract support [1]. Expected to begin later this year or early next year, the study will enroll more than 700 adults in South Texas, potentially closer to 1,000, aged 60 to 65 and in relatively good health.
For a field often criticized for moving faster in headlines than in hard evidence, that alone is the story.
“This is the culmination of 50 years’ worth of aging research at UT Health San Antonio,” said Dr Elena Volpi, director of UT Health San Antonio’s Sam and Ann Barshop Institute for Longevity and Aging Studies, and lead author of the study [2].
The longevity space is full of seductive language: reversal, optimization, extension, biohacking. But beneath these, there has not yet been a large human trial specifically designed to prove that a drug can slow biological aging. That is what makes VITAL-H feel different. The trial is built around three drugs already in circulation – medicines doctors already know, patients already take and regulators have already approved for other uses.
If one of these drugs shows a clear signal, the field does not need to start from scratch. It can move from scientific curiosity to clinical relevance much faster.
Three familiar drugs, one unfamiliar role
The three drugs in VITAL-H arrive with very different reputations.
Rapamycin is the veteran of antiaging speculation. Originally approved in 1999 as an immune system suppressant, it became a longevity touchstone after a 2009 study found that low doses extended lifespan in mice. In plain terms, it was one of the first major signs that a pill – not just a gene mutation or calorie restriction – might meaningfully influence aging in a mammal.
That gave rapamycin a near-mythic status in some longevity circles. But myth is not medicine. Mouse data can point the way, but it cannot close the case.
Semaglutide, by contrast, is already a household name. Known through brands such as Ozempic and Wegovy, it exploded into public consciousness as a diabetes treatment and weight-loss drug. Yet its scientific story has become much broader than that. Researchers have increasingly linked GLP-1 drugs to benefits across a surprising range of age-related conditions, from cardiovascular risk to sleep apnea, fatty liver disease and chronic kidney disease.
That has pushed a once-simple question: are these drugs helping because people lose weight, or are they also affecting deeper systems involved in aging itself?
Then there is dapagliflozin, the least famous name in the trio, but arguably the most quietly intriguing. Used to treat diabetes, it helps the body flush excess glucose through urine. That sounds unglamorous, but the downstream effects are what interest longevity researchers. The drug appears to reduce low-grade chronic inflammation – the kind of background biological stress that slowly wears the body down over time, often described as “inflammaging.”
If aging is like a machine gradually collecting rust, these drugs are not magic replacements for the parts. The question is whether they can slow the corrosion.
‘About health span, not immortality’
Importantly, VITAL-H is not trying to prove that people can live forever, or even necessarily much longer. That is a useful correction in a sector that sometimes mistakes spectacle for substance.
Because measuring human lifespan would take decades, researchers will instead track biological markers of aging and a newer metric known as intrinsic capacity, developed by the World Health Organization (WHO). Think of it less as counting birthdays and more as asking a harder question: how well are you still functioning?
Can you move well? Sleep well? Think clearly? Maintain strength? Protect your heart? Stay independent? That is the kind of aging most people actually care about.
Participants will be divided into four groups: rapamycin, semaglutide, dapagliflozin and placebo. They will wear Oura rings and return for regular check-ins, allowing researchers to gather a steady stream of health data rather than occasional snapshots.
“What we’re looking for is for people to gain more years of health,” Volpi said. “Our hope is that at least one of these drugs will show an impact on slowing down the decline in intrinsic capacity that occurs with aging. We want to slow it down so that people can gain more years of healthy living, healthy life.”
The longevity field is slowly moving away from the fantasy of defeating death and toward something more democratic, more humane and more medically useful: compressing decline.
As Volpi put it: “We want to start the declining process as late as possible to compress the decline towards the end of life so that we can live and work and be happy and do whatever we want to do for as long as we can.”
A better longevity story (and a more inclusive one)
There is another reason this study stands out: who it is trying to include. Volpi said the team plans to recruit deeply across South Texas, focusing on a Hispanic population that has historically been underrepresented in research.
“We will try to get deep into South Texas, because we want to give an opportunity to people who cannot normally participate in clinical trials to actually participate,” Volpi said. “Because we think it is important that everyone has a chance.”
That may sound like a logistical detail, but in longevity, it is political in the best sense of the word. A field cannot claim to be building the future of aging if its evidence is drawn from a narrow, privileged slice of the population.
If longevity is going to become real medicine rather than a boutique aspiration, the trials have to look more like the world.
VITAL-H may not deliver a miracle. It may not crown a single “antiaging drug.” It may even produce mixed results, which in this field could be the most honest outcome of all, but that does not diminish its importance.
What longevity needs now is not another wave of overpromises. It needs well-powered, human-centered studies that ask the right questions in the right population using outcomes that matter in everyday life. That is what this trial represents.
If one of these drugs works, the implications could be enormous: a faster path for drug repurposing, stronger confidence from investors, and a more credible bridge between academic geroscience and real-world clinical care. And if none of them do, that would move the field forward as well.
Photographs courtesy of Sam and Ann Barshop Institute for Longevity and Aging Studies at UT Health San Antonio.
[1] https://news.uthscsa.edu/ut-san-antonio-to-lead-38-million-national-trial-testing-drugs-to-extend-healthspan/
[2] https://sanantonioreport.org/study-drugs-slow-aging-ut-health-san-antonio/
